+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viral Vectors And Plasmid DNA Manufacturing Market Size By Product Type, By Application, By End Product, By Geographic Scope And Forecast

  • Report

  • 114 Pages
  • June 2021
  • Region: Global
  • Verified Market Research
  • ID: 5440556
According to the publisher, the Global Viral Vectors and Plasmid DNA Manufacturing Market was valued at USD 583.71 Million in 2020 and is projected to reach USD 1,866.90 Million by 2028, growing at a CAGR of 15.40% from 2021 to 2028.



The Viral Vectors And Plasmid DNA Manufacturing Market report provides a holistic evaluation of the market for the forecast period. The report comprises of various segments as well an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics, involves the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Viral Vectors And Plasmid DNA Manufacturing Market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.

Global Viral Vectors And Plasmid DNA Manufacturing Market Overview


A growing number of patients opting for gene therapy is a major factor propelling the growth of the Viral Vectors and Plasmid DNA Manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various disease. Genetically modified therapies have emerged as a promising treatment approach for various diseases (primarily ones that currently have no cure), including inherited disorders and certain viral infections. Demand for plasmid DNA is rising steeply because of a boom in gene therapy development.

This report provides an all-inclusive environment of the analysis for the Viral Vectors And Plasmid DNA Manufacturing Market. The market estimates provided in the report are the result of in-depth secondary research, primary interviews and in-house expert reviews. These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Viral Vectors And Plasmid DNA Manufacturing Market growth.

Along with the market overview, which comprises of the market dynamics the chapter includes a Porter’s Five Forces analysis which explains the five forces: namely buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Viral Vectors And Plasmid DNA Manufacturing Market. It explains the various participants, such as system integrators, intermediaries and end-users within the ecosystem of the market. The report also focuses on the competitive landscape of the Viral Vectors And Plasmid DNA Manufacturing Market.

Viral Vectors And Plasmid DNA Manufacturing Market: Segmentation Analysis


The Global Viral Vectors And Plasmid DNA Manufacturing Market is Segmented on the basis of Product Type, Application, End Product, And Geography.

Key Players in The Market


The “Global Viral Vectors And Plasmid DNA Manufacturing Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience, Laboratories, Inc. (ABL, Inc.), Novasep Holding S.A.S, ATVIO Biotech Ltd, and Others.
Frequently Asked Questions about the Viral Vectors And Plasmid DNA Manufacturing Market

What is the estimated value of the Viral Vectors And Plasmid DNA Manufacturing Market?

The Viral Vectors And Plasmid DNA Manufacturing Market was estimated to be valued at $583.71 Million in 2020.

What is the growth rate of the Viral Vectors And Plasmid DNA Manufacturing Market?

The growth rate of the Viral Vectors And Plasmid DNA Manufacturing Market is 15.6%, with an estimated value of $1866.9 Million by 2028.

What is the forecasted size of the Viral Vectors And Plasmid DNA Manufacturing Market?

The Viral Vectors And Plasmid DNA Manufacturing Market is estimated to be worth $1866.9 Million by 2028.

Who are the key companies in the Viral Vectors And Plasmid DNA Manufacturing Market?

Key companies in the Viral Vectors And Plasmid DNA Manufacturing Market include Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience and Laboratories Inc..

Table of Contents

1 Introduction
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations
2 Research Methodology
2.1 Data Mining
2.2 Secondary Research
2.3 Primary Research
2.4 Subject Matter Expert Advice
2.5 Quality Check
2.6 Final Review
2.7 Data Triangulation
2.8 Bottom-Up Approach
2.9 Top Down Approach
2.10 Research Flow
2.11 Key Insights from Industry Experts
2.12 Data Sources
3 Executive Summary
3.1 Market Overview
3.2 Global Viral Vectors and Plasmid Dna Manufacturing Market Regional Insights
3.3 Global Viral Vectors and Plasmid Dna Manufacturing Market Geographical Analysis (Cagr %)
3.4 Global Viral Vectors and Plasmid Dna Manufacturing Market, by Product Type (Usd Million)
3.5 Global Viral Vectors and Plasmid Dna Manufacturing Market, by Application (Usd Million)
3.6 Global Viral Vectors and Plasmid Dna Manufacturing Market, by End Product (Usd Million)
3.7 Future Market Opportunities
3.8 Global Market Split
4 Market Outlook
4.1 Global Viral Vectors and Plasmid Dna Manufacturing Market Outlook
4.2 Market Drivers
4.2.1 Increasing Number of Patients Opting for Gene Therapy
4.2.2 Rising Prevalence of Hiv/Aids and Growing R&D Funding from Several Organizations
4.3 Restraints
4.3.1 Manufacturing Challenges Pertaining to Large Scale Production of Vectors
4.4 Opportunities
4.4.1 Growing Healthcare Infrastructure and Government Support
4.4.2 Growing Number of Gene Therapy Candidates, Coupled With Their Rapid Progression Through Various Phases of Clinical Development
4.5 the Impact of Covid-
4.6 Porters Five Force Model
4.7 Product Life Line
5 Market, by Product Type
5.1 Overview
5.2 Viral Vector
5.3 Plasma Dna
5.4 Non-Viral Dna Vectors
6 Market, by Application
6.1 Overview
6.2 Cancer
6.3 Inherited Disorder
6.4 Infectious Diseases
6.5 Others
7 Market, by End Product
7.1 Overview
7.2 Dna Vaccines
7.3 Gene Therapy
7.4 Immunotherapy
7.5 Others
8 Market, by Geography
8.1 Overview
8.2 North America
8.2.1 North America Market Snapshot
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Market Snapshot
8.3.2 Germany
8.3.3 U.K.
8.3.4 France
8.3.5 Rest of Europe
8.4 Asia-Pacific
8.4.1 Asia-Pacific Market Snapshot
8.4.2 China
8.4.3 Japan
8.4.4 India
8.4.5 Rest of Apac
8.5 Row
8.5.1 Row Market Snapshot
8.5.2 Middle East and Africa
8.5.3 Latin America
9 Competitive Landscape
9.1 Overview
9.2 Competitive Scenario
9.3 Company Market Ranking Analysis
10 Company Profiles
10.1 Brammer Bio (Thermo Fisher Scientific Inc.)
10.1.1 Company Overview
10.1.2 Company Insights
10.1.3 Segment Breakdown
10.1.4 Product Benchmarking
10.1.5 Key Developments
10.1.6 SWOT Analysis
10.2 Merck Kgaa
10.2.1 Company Overview
10.2.2 Company Insights
10.2.3 Segment Breakdown
10.2.4 Product Benchmarking
10.2.5 Key Developments
10.2.6 SWOT Analysis
10.3 Lonza
10.3.1 Company Overview
10.3.2 Company Insights
10.3.3 Segment Breakdown
10.3.4 Product Benchmarking
10.3.5 Key Developments
10.3.6 SWOT Analysis
10.4 Fujifilm Diosynth Biotechnologies U.S.A. Inc.
10.4.1 Company Overview
10.4.2 Company Insights
10.4.3 Product Benchmarking
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5 Advanced Bioscience Laboratories, Inc (Abl Inc.)
10.5.1 Company Overview
10.5.2 Company Insights
10.5.3 Product Benchmarking
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Cobra Biologics Ltd.
10.6.1 Company Overview
10.6.2 Company Insights
10.6.3 Product Benchmarking
10.6.4 Key Developments
10.7 Waisman Biomanufacturing
10.7.1 Company Overview
10.7.2 Company Insights
10.7.3 Product Benchmarking
10.8 Genezen Laboratories
10.8.1 Company Overview
10.8.2 Company Insights
10.8.3 Product Benchmarking
10.8.4 Key Developments
10.9 Yposkesi, Inc.
10.9.1 Company Overview
10.9.2 Company Insights
10.9.3 Product Benchmarking
10.9.4 Key Developments
10.10 Novasep Holding Sas
10.10.1 Company Overview
10.10.2 Company Insights
10.10.3 Product Benchmarking
10.10.4 Key Developments
11 Appendix
11.1 Related Report

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Merck KGaA
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
  • Cobra Biologics Ltd.
  • Brammer Bio
  • Waisman Biomanufacturing
  • Genezen
  • YPOSKESI
  • Advanced BioScience
  • Laboratories Inc.
  • Novasep Holding S.A.S
  • ATVIO Biotech Ltd

Methodology

Loading
LOADING...